Mizuho analyst Graig Suvannavejh raised the firm’s price target on Immunocore to $90 from $86 and keeps a Buy rating on the shares following the Q4 report. The firm sates multiple data read outs are expected throughout 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMCR:
- Immunocore price target raised to $87 from $85 at Oppenheimer
- Immunocore Holdings Q4 and Full-Year 2023 Earnings Presentation
- Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
- Immunocore reports Q4 EPS (40c), consensus (28c)
- Immunocore enters trial collaboration, supply agreement with Bristol Myers
